Status and phase
Conditions
Treatments
About
The goal of this clinical trial is to develop a new cancer diagnostic and prognostic tool based on the dynamic and non-invasive detection of an exogenous volatile molecule, i.e., ethanol, from patients' samples.
Patients' blood plasma will be analyzed with a mixture of volatile organic compound-based probes, each targeting a specific glycosidase. The presence of a given glycosidase in a blood sample would thus be revealed by the detection of an ethanol isotope in the gas phase.
3 groups of patients with localized cancer (breast, prostate, pancreas) will be enrolled, as well as 1 group of patient without any cancer (control group).
For the patients, two 5ml plasma samples will be collected, one before and one after surgery for localized cancers. For healthy volunteers, only one 5ml plasma sample will be collected.
The primary objective will be to compare the levels of glycosidases measured in the blood of patients followed for localized cancer and referred for first surgery compared to control patients without cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Group 2: 40 patients with definitively diagnosed, untreated, localized solid lung cancer referred for initial surgical treatment.
Group 3: 40 patients with definitively diagnosed, untreated, localized solid pancreatic cancer referred for initial surgical treatment.
Group 4: 100 control patients with no cancer diagnosis or history of solid or hematological cancer.
Exclusion criteria
Specific criteria for groups 1, 2, and 3:
Primary purpose
Allocation
Interventional model
Masking
220 participants in 4 patient groups
Loading...
Central trial contact
Sheik Emambux, MD PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal